TITLE

COMMENTARY: Simvastatin was cost-effective across a broad range of risk and age groups

AUTHOR(S)
Bryson, Chris L.; Fihn, Stephan D.
PUB. DATE
March 2007
SOURCE
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the authors' comment on the Heart Protection Study, which was aimed at determining the cost and benefits of treating patients with a generic statin dose. According to the authors, the costs of care will differ in different settings, even assuming similar drug prices. Moreover, it is stated that as the amount of risk reduction resulting from statin therapy varies, it is very difficult to make accurate predictions of benefit among low-risk patients.
ACCESSION #
24685694

 

Related Articles

  • Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. Cheng, Caroline W. R.; Kam-Sang Woo; Chan, Juliana C. N.; Tomlinson, Brian; You, Joyce H. S. // American Journal of Health-System Pharmacy;2/15/2005, Vol. 62 Issue 4, p411 

    Compares the accuracy of patient self-report and pill count in measuring patient adherence to statin therapy in Hong Kong. Device utilized to monitor the medication activity and administration in Chinese patient; Assessment on the adherence of subject to therapeutic and the drug dosage...

  • Generic simvastatin would be cost effective for more people in US.  // PharmacoEconomics & Outcomes News;4/4/2009, Issue 575, p1 

    The article discusses a study of statin cost-effectiveness in the U.S. for people at different vascular risk levels. Based on the results, the Heart Protection Study (HPS) Collaborative Group believe that guidelines should be modified to extend statin treatment to a wider population. A Markov...

  • Norwegians to receive simvastatin in first instance.  // PharmacoEconomics & Outcomes News;5/7/2005, Issue 477, p14 

    Reports that simvastatin will become a preferred product for reimbursement in Norway starting June 1, 2005. Provisions of the reimbursement criteria; Cost-effectiveness of the drug.

  • Statins for all patients with diabetes? Kirchner, Jeff; Russell, John J. // Patient Care;Aug2003, Vol. 37 Issue 8, p68 

    Discusses research being done on statin as treatment for patients with diabetes. Reference to a study by R. Collins et al published in the 2003 issue of "Lancet"; Explanation on diabetes; Findings of the study.

  • Controversial concerns over relative rosuvastatin safety.  // Reactions Weekly;6/4/2005, Issue 1054, p3 

    Discusses research being done on the safety of rosuvastatin, a statin used in common clinical practice. Reference to a study by A. A. Alsheikh-Ali et al published in the 2005 issue of "Circulation"; Findings of the study.

  • It's Important To Monitor This Statin Carefully.  // RN;Dec2004, Vol. 67 Issue 12, p72 

    Reminds healthcare providers to carefully follow dosage recommendations for rosuvastatin (Crestor) to minimize the risk of myopathy. Astra-Zeneca Pharmaceuticals' revision of the package insert for use in European countries; Report of adverse events in overseas patients taking the drug.

  • Research brief: Statins and acute coronary syndrome.  // GP: General Practitioner;9/6/2004, p10 

    The article cites that patients given 40mg/day simvastatin for a month followed by 80mg/day thereafter did not have a better outcome at the acute coronary event than those given placebo for four months followed by 20mg/day simvastatin. The international trial involving more than 4,400 patients...

  • New prescribing advice for Crestor in Europe and FDA issues reminder.  // Reactions Weekly;6/19/2004, Issue 1006, p2 

    Reports on a letter issued by AstraZeneca to health professionals to advise of new prescribing information on the maximum dose of Crestor or rosuvastatin in 2004. Reason for the issuance of the prescribing advice; Daily dose of rosuvastatin recommended by AstraZeneca; Details of a public...

  • Gemfibrozil/simvastatin interaction.  // Reactions Weekly;9/12/2009, Issue 1269, p21 

    The article describes the case of an 83-year-old man who developed rhabdomyolysis following the addition of gemfibrozil to his simvastatin treatment. Particular focus is given to his medical history and dosing regimen. He experienced lower extremity weakness. The results of his laboratory...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics